Methylation Profiling in Diffuse Gliomas: Diagnostic Value and Considerations

Cancers (Basel). 2022 Nov 18;14(22):5679. doi: 10.3390/cancers14225679.

Abstract

Diffuse gliomas cause significant morbidity across all age groups, despite decades of intensive research efforts. Here, we review the differences in diffuse gliomas in adults and children, as well as the World Health Organisation (WHO) 2021 classification of these tumours. We explain how DNA methylation-based classification works and list the methylation-based tumour types and subclasses for adult and paediatric diffuse gliomas. The benefits and utility of methylation-based classification in diffuse gliomas demonstrated to date are described. This entails the identification of novel tumour types/subclasses, patient stratification and targeted treatment/clinical management, and alterations in the clinical diagnosis in favour of the methylation-based over the histopathological diagnosis. Finally, we address several considerations regarding the use of DNA methylation profiling as a diagnostic tool, e.g., the threshold of the classifier, the calibrated score, tumour cell content and intratumour heterogeneity.

Keywords: MGMT; calibrated score; classification; diffuse gliomas; glioblastoma; heterogeneity; intratumour; methylation.

Publication types

  • Review